Matinas BioPharma announces publication of in vivo efficacy of MAT2203

Matinas BioPharma Holdings announces that MAT2203, its oral formulation of the potent antifungal amphotericin B, demonstrated efficacy compared with placebo in treating the pulmonary mucormycosis fungal infections Rhizopus delemar and M. circinelloides f. jenssenii in immunosuppressed mice. Efficacy was demonstrated by prolonged median survival time, enhanced overall survival, reduced tissue fungal burden of target organs and improved histological architecture of infected lungs. In addition, MAT2203 activity appeared to be similar to IV-amphotericin B in survival studies in the M. circinelloides f. jenssenii mouse model. The study results are reported in the manuscript “Efficacy of an oral lipid nanocrystal formulation of amphotericin B in the neutropenic mouse model of pulmonary mucormycosis” published in the peer-reviewed Journal of Antimicrobial Agents and Chemotherapy. “The promising outcomes of MAT2203 in these studies represent a significant step towards a less invasive and safer treatment approach to combating invasive mucormycosis, since unlike liposomal amphotericin B which is given intravenously, MAT2203 is administered orally and can be administered long-term without any of the significant toxicities associated with LAMB treatment,” said lead manuscript author Ashraf Ibrahim, PhD at the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. “It’s a testament to the potential of innovative drug delivery systems like lipid nanocrystals in transforming how we treat infectious diseases.”